The role of glimepiride in the effective management of Type 2 diabetes

被引:78
作者
Davis, SN [1 ]
机构
[1] Vanderbilt Univ, Sch Med, Div Endocrinol Diabet & Metab, Nashville, TN 37232 USA
关键词
diabetes; sulfonylureas; glimepiride; glucose;
D O I
10.1016/j.jdiacomp.2004.07.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 2 diabetes mellitus, a disorder of impaired insulin secretion and insulin resistance, has reached epidemic proportions. The effective management of Type 2 diabetes is of vital concern to clinicians. The identification of high-risk individuals and lifestyle management can help control diabetes; however, most patients require pharmacologic intervention. The goals of pharmacologic therapy are to achieve adequate glycemic control while avoiding hypoglycemia and weight gain and to minimize the risk of future micro- and macrovascular complications. There are a number of available glucose-lowering agents from which to choose. This review focuses on the sulfonylureas, the first oral agents introduced for the management of Type 2 diabetes, which are effective, well-tolerated, and well-established drugs, Second-generation sulfonylureas are now widely used in the management of Type 2 diabetes. The most recent addition, glimepiride, can be used in combination with metformin, the thiazolidinediones, alpha-glucosidase inhibitors, and insulin. The unique properties of glimepiride may provide advantages over other currently available insulin secretagogues. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:367 / 376
页数:10
相关论文
共 70 条
[1]   Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients [J].
Alvarsson, M ;
Sundkvist, G ;
Lager, I ;
Henricsson, M ;
Berntorp, K ;
Fernqvist-Forbes, E ;
Steen, L ;
Westermark, G ;
Westermark, P ;
Örn, T ;
Grill, V .
DIABETES CARE, 2003, 26 (08) :2231-2237
[2]  
*AM COLL END, 2002, ENDOCR PRACT S1, V8, P5
[3]  
American Diabetes Association, 2003, DIABETES CARE S1, V26, pS1, DOI DOI 10.2337/DIACARE.26.2007.S1
[4]  
[Anonymous], 1990, METABOLISM, V39, P905, DOI 10.1016/0026-0495(90)90299-R
[5]  
[Anonymous], 1995, Diabetes, V44, P1249
[6]  
[Anonymous], 2003, NAT DIAB FACT SHEET
[7]   Low-dose oral glyburide reduces glucose production rates in patients with impaired fasting glucose [J].
Bavirti, S ;
Tayek, JA .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2003, 52 (04) :407-412
[8]   COMPARATIVE EFFICACY OF A ONCE-DAILY CONTROLLED-RELEASE FORMULATION OF GLIPIZIDE AND IMMEDIATE-RELEASE GLIPIZIDE IN PATIENTS WITH NIDDM [J].
BERELOWITZ, M ;
FISCHETTE, C ;
CEFALU, W ;
SCHADE, DS ;
SUTFIN, T ;
KOURIDES, IA .
DIABETES CARE, 1994, 17 (12) :1460-1464
[9]   Interaction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans [J].
Bijlstra, PJ ;
Lutterman, JA ;
Russel, FGM ;
Thien, T ;
Smits, P .
DIABETOLOGIA, 1996, 39 (09) :1083-1090
[10]   The sulfonylurea controversy: More questions from the heart [J].
Brady, PA ;
Terzic, A .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 31 (05) :950-956